Driving a Return Back To Normal Life

AbC-19™ is a rapid antibody test used for the detection of SARS-CoV-2 (COVID-19) neutralising antibodies in response to infection or following vaccination.

The test detects SARS-CoV-2 neutralising antibodies from a small finger prick of blood in only 20 minutes and detects whether someone has produced an immune response to COVID-19 infection or receiving vaccination.

AbC-19™ is CE marked for use by healthcare professionals across the UK and EU.

The AbC-19™ Antibody Rapid Test has the potential to let people know their immune status and can help employers, aviation and events organisers know who has immunity, limiting risk and helping to make more informed decision making:

Why use AbC-19™ Rapid Test?

  • Confirms the presence of SARS-CoV-2 IgG neutralising antibodies in a small blood sample
  • Will identify historical infection and immune resposnse to the COVID-19 vaccine
  • Sensitivity: 98.03%, Specificity: 99.56%*
  • Minimal operator training required
  • CE marked for use by healthcare professionals only
  • For use in multiple testing locations including workplaces, pharmacies or clinical settings including doctors’ surgeries


AbC-19™ Rapid Test and Vaccines

Vaccines “train” the immune system to have a response to a virus, by using harmless viruses that have been altered to resemble the harmful ones. In the case of SARS-CoV-2 vaccine, developers have focused on mimicking the Spike protein of the coronavirus. Three of the leading vaccine candidates all feature full-length SARS-CoV-2 spike trimers: Oxford University / AstraZeneca, Pfizer / BioNTech, and Moderna, which trigger the production of IgG neutralising antibodies. It is this immune response that is detected in a fingerpick blood sample by the AbC-19™ Rapid Test.


Professor Lawrence S. Young, Virologist at University of Warwick Medical School:

”The AbC-19™ Rapid Test targets the IgG antibodies to the full spike protein of the SARS-CoV-2 virus and therefore has the potential to help identify the immune system’s response to the current three Medicines and Healthcare products Regulatory Agency (MHRA) approved vaccines.

The assay could help establish whether people’s immune systems are responding to the vaccine in the right way, and, ultimately, could be predictive of a protective immune response”


*14 days post onset of symptoms